$VACHU News
Last published 1y ago
- 1y agoVACHVACHUVACHWVERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer TherapiesGlobeNewswireVERAXA's Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE")
- 2y agoVACHVACHUVoyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024GlobeNewswireBROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (NASDAQ:VACHU) (the "Company") announced that holders of the units sold in the Company's initial public offering of 25,300,000 units, which
- 2y agoVACHVACHUVoyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public OfferingGlobeNewswireBROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (NASDAQ:VACHU) (the "Company") today announced that it closed its initial public offering of 25,300,000 units at $10.00 per unit, including
- 2y agoVACHVACHUVoyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public OfferingGlobeNewswireBROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (NASDAQ:VACHU) (the "Company") announced today the pricing of its initial public offering of 22,000,000 units at $10.00 per unit. The units